The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
108
About the Report
About the Report
Summary
The National Institute of Allergy and Infectious Diseases (NIAID), a subsidiary of National Institutes of Health is a research institute that provides technological and therapeutic solutions. The institute develops therapies, diagnostic tests, vaccines, and other technologies to understand, immunologic, treat and prevent infectious, and allergic diseases. It offers services such as grants and funding, research and training, and health information. NIAID supports basic and clinical research to understand the causes and mechanisms that lead to the development of allergic and immunologic diseases. The institute's research areas include infectious diseases such as tuberculosis and influenza, HIV/AIDS, biodefense; and immune-mediated diseases including asthma and allergy. NIAID is headquartered in Bethesda, Maryland, the US.
The National Institute of Allergy and Infectious Diseases-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
The National Institute of Allergy and Infectious Diseases, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16
Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18
Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19
DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22
RedHill Biopharma Enters into Agreement with NIAID 23
GlaxoSmithKline Enters into Research Agreement with NIAID 24
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27
GenVec Enters into Research Agreement with LMIV 28
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33
Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37
Licensing Agreements 38
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40
The National Institute of Allergy and Infectious Diseases-Key Competitors 41
The National Institute of Allergy and Infectious Diseases-Key Employees 42
The National Institute of Allergy and Infectious Diseases-Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Government and Public Interest 44
Sep 12, 2018: TechnoVax awarded USD 1.5 million NIH grant to further develop a universal VLP-based influenza vaccine 44
Aug 28, 2018: UTEP Scientists Awarded USD 6M to Improve Treatment for Chagas Disease 45
Aug 02, 2018: UMD-Led team receives USD 7.7 Million NIH grant for first-of-its-kind tick-borne disease research 46
Jul 25, 2018: HIV remission free of antiretroviral therapy is a feasible goal 47
Jul 11, 2018: NIAID scientists create 3D structure of 1918 influenza virus-like particles 48
Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 49
Jun 21, 2018: VTCRI scientist awarded USD 2 million grant from the National Institutes of Health to study the body's immune memory response 50
May 30, 2018: NIH scientists show how tularemia bacteria trick cells to cause disease 52
May 16, 2018: Lab-confirmed prenatal exposure to Zika is linked to cardiac defects in infants 53
Apr 25, 2018: Anti-HIV drug combination does not increase preterm birth risk, study suggests 54
Apr 16, 2018: Epstein-Barr virus protein can switch on risk genes for autoimmune diseases 55
Mar 27, 2018: NIAID Scientists Discover Rare Genetic Cause of Crohn's Disease 56
Mar 22, 2018: NIH scientists say advanced vaccines could limit future outbreaks 57
Mar 21, 2018: Islet transplantation improves quality of life for people with hard-to-control type 1 diabetes 58
Mar 19, 2018: Newly described human antibody prevents malaria in mice 60
Mar 09, 2018: NIH experts call for transformative research approach to end tuberculosis 61
Mar 08, 2018: NIAID scientists assess transmission risk of familial human prion diseases to mice 62
Mar 08, 2018: Monoclonal antibodies crucial to fighting emerging infectious diseases, say NIH officials 63
Mar 05, 2018: Broadly neutralizing antibody treatment may target viral reservoir in monkeys 64
Feb 28, 2018: NIAID unveils strategic plan for developing a universal influenza vaccine 65
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 66
Feb 05, 2018: New Research Suggests Your Immune System Can Protect Against MRSA Infections 67
Jan 24, 2018: NIH begins large HIV treatment study in pregnant women 69
Jan 03, 2018: Stem cell transplant for severe scleroderma improves survival, quality of life 71
Dec 05, 2017: Scientists Find Potential Weapons for the Battle Against Antibiotic Resistance 73
Dec 04, 2017: Fighting HIV through a better delivery method of anti-retrovirals 75
Nov 30, 2017: New treatment investigated for brain tapeworm infection 76
Oct 24, 2017: Identifying the mechanism for a new class of antiviral drugs could hasten their approval 77
Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 78
Sep 28, 2017: Neuro-Immune Crosstalk in Allergic Asthma 80
Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 82
Sep 20, 2017: Texas Biomed Scientists part of USD 11.5 million NIH project aimed at combating drug resistance in the malaria parasite 84
Sep 05, 2017: Zika virus selectively infects and kills glioblastoma cells in mice 85
Aug 22, 2017: CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis 86
Aug 21, 2017: Texas Biomed part of team receiving five-year, USD 4.4 million NIH grant for novel TB vaccine testing 87
Jul 31, 2017: Biomedical Researcher Gets USD 1.9 Million to Study Influenza Vaccines and Cross-Protective Immunity Biomedical Researcher Gets USD 1.9 Million to Study Influenza Vaccines and Cross-Protective Immunity 89
Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 90
Jul 13, 2017: Experimental Zika Virus Vaccines Restrict In Utero Virus Transmission in Mice 91
Jun 19, 2017: USD 3.6 Million NIH Grant Awarded to NYBC Scientist for Research on River Blindness Vaccine 92
May 01, 2017: NIH Research Improves Health for People with Asthma 93
Apr 21, 2017: Researchers receive USD 9 million grant for research on drug-resistant malaria 95
Feb 01, 2017: Stem cell transplants may induce long-term remission of multiple sclerosis 96
Jan 17, 2017: NIAID Awards Paragon Bioservices a Multiple Award IDIQ Contract valued up to USD 159M for Preclinical Drug Development Services 97
Product News 98
Oct 03, 2017: Oak Therapeutics Announces Results of Bioequivalence Study of Company's Oral Dissolvable Strip for Tuberculosis 98
Jun 12, 2018: GenScript Supports the Development of a Novel HIV Vaccine 99
May 07, 2018: NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV-positive recipients 100
May 03, 2018: Bacteria therapy for eczema shows promise in NIH study 102
Mar 13, 2018: NIH scientists describe potential antibody approach for treating multidrug-resistant Klebsiella pneumoniae 104
Other Significant Developments 105
Apr 09, 2018: NIH Scientists Develop Macaque Model to Study Crimean-Congo Hemorrhagic Fever 105
Feb 21, 2018: NIH program to accelerate therapies for arthritis, lupus releases first datasets 106
Jan 24, 2017: NIH Advances Understanding of Defenses Against Antibiotic-Resistant Klebsiella Bacteria 107
Appendix 108
Methodology 108
About GlobalData 108
Contact Us 108
Disclaimer 108
List of Figure
List of Figures
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Key Facts 2
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
The National Institute of Allergy and Infectious Diseases, Deals By Therapy Area, 2012 to YTD 2018 10
The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11
The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15
Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16
Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17
Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18
Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19
DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20
Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21
Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22
RedHill Biopharma Enters into Agreement with NIAID 23
GlaxoSmithKline Enters into Research Agreement with NIAID 24
PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25
SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26
Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27
GenVec Enters into Research Agreement with LMIV 28
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29
BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30
Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31
PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33
Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35
DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37
Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38
Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39
Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40
The National Institute of Allergy and Infectious Diseases, Key Competitors 41
The National Institute of Allergy and Infectious Diseases, Key Employees 42
The National Institute of Allergy and Infectious Diseases, Subsidiaries 43
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.